Table 1. Baseline characteristics and comparison of results.

Values are given in numbers (percentages).

M, Male; F, Female; Yr, Year; CKD, Chronic kidney disease; TRx, Transplant recipient; AKI, Acute kidney injury; COVID-19, Coronavirus disease 2019; BUN, Blood urea nitrogen; Cr, Creatinine; eGFR, Estimated glomerular filtration rate; IVIG, Intravenous immunoglobulin.

[2], [4], [11-13]

Author /Year	Cheng Y, et al. (2020)	Chen T, et al. (2020)	Gandolfini I, et al. (2020)	Wang L, et al. (2020)	Zhang H, et al. (2020)	Total
Study location	China	China	Italy	China	China
Number of patients	701	274	2	116	5	1098
M	367 (52%)	171 (62%)	1 (50%)	67 (58%)	4 (80%)	610 (55%)
F	334 (48%)	103 (38%)	1 (50%)	49 (42%)	1 (20%)	488 (45%)
Median age (Yr)	63	62	64	54	45
Patients with known CKD or TRx	14 (2%)	4 (1%)	2 (100%)	5 (4%)	5 (100%)	30 (3%)
Patients with AKI after COVID-19 infection	36 (5%)	29 (10%)	1 (50%)	0 (0%)	0 (0%)	66 (6%)
On admission: BUN/Cr (mg/dL) (mean)	-	13.72 / 0.86	- / 2.3	With CKD: 89.83±24.03 / 10.62±1.34   Without CKD: 14.65±4.82 / 0.88±0.29	33.27±20.08 / 2.10±1.44
Change in BUN/Cr (mg/dL) (mean)	-	23.52 / 0.99	- / 2.8	With CKD: 89.44±25.71 / 10.34±1.85 Without CKD: 14.53±5.80 / 0.82±0.28	-
Change in eGFR (mL/min) (mean)	-	-	-	With CKD: 14.43±7.34 to 22.86±9.37 Without CKD: 129.81±10.33 to 127.96±9.65	-
Mortality with AKI	34 (94%)	28 (96%)	0 (0%)	0 (0%)	0 (0%)	62 (94%)
Mortality without AKI	79 (12%)	85 (35%)	1 (100%)	7 (6%)	0 (0%)	172 (17%)
Major treatment provided (including mechanical ventilation)	Arbidol, interferon, lopinavir and ritonavir, glucocorticoids, antibiotics	Antivirals, glucocorticoids, IVIGs, antibiotics, interferon	Hydroxychloroquine, lopinavir + ritonavir, or darunavir + cobicistat, colchicine	-	Antiviral (oseltamivir or arbidol), antibacterial therapy (cefixime), IVIGs, triple immunosuppression with glucocorticoids, mycophenolate mofetil and calcineurin inhibitors